Novel Type 1 and Type 3 Live Attenuated Oral Poliovirus Vaccines Show Comparable Safety, Immunogenicity, and Shedding to Sabin mOPV in First‑in‑Human Phase 1 Trial
Highlight
– First-in-human, observer-masked phase 1 trial shows novel type 1 and type 3 oral poliovirus vaccines (nOPV1, nOPV3) are well tolerated in healthy adults.
– Immunogenicity (homotypic neutralising antibody responses) after a single dose was high (86–100% seroconversion for nOPV; 86–93% for mOPV); seroprotection at 28 days reached 100%.
– Faecal viral shedding kinetics and peak detection by PCR were similar between nOPV and Sabin monovalent OPV (mOPV); peak shedding reached 100% by PCR on day 8 in IPV recipients.
– Results support advancement of nOPV1 and nOPV3 into phase 2 trials, while further evaluation in children, immunocompromised hosts, and population-level genetic stability remains essential.
Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.